Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

Blood

Volumn 113, Issue 24, 2009, Pages 6206-6214

  Nervi, Bruno ^a   Ramirez, Pablo ^a   Rettig, Michael P ^a   Uy, Geoffrey L ^a   Holt, Matthew S ^a   Ritchey, Julie K ^a   Prior, Julie L ^a   Piwnica Worms, David ^a,b   Bridger, Gary ^c   Ley, Timothy J ^a   DiPersio, John F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN G; CHEMOKINE RECEPTOR CXCR4; CYTARABINE; FIREFLY LUCIFERASE; PLERIXAFOR; RETINOIC ACID RECEPTOR ALPHA; STROMAL CELL DERIVED FACTOR 1; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CATHEPSIN; CXCR4 PROTEIN, MOUSE; HETEROCYCLIC COMPOUND; SERINE PROTEINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CELL MIGRATION; CHEMOSENSITIZATION; COCULTURE; CONTROLLED STUDY; IN VITRO STUDY; LEUKEMIA CELL; LEUKOSTASIS; MICROENVIRONMENT; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN; STROMA CELL; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; BONE MARROW; C57BL MOUSE; CLONOGENIC ASSAY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL LEUKEMIA; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROMYELOCYTIC LEUKEMIA; PROTEIN TRANSPORT; STEM CELL MOBILIZATION; TRANSPLANTATION; TUMOR CELL CULTURE;

ANIMALS; ANTI-HIV AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BONE MARROW; CATHEPSINS; COLONY-FORMING UNITS ASSAY; CYTARABINE; DRUG SYNERGISM; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, INBRED C57BL; PROTEIN TRANSPORT; RECEPTORS, CXCR4; SERINE ENDOPEPTIDASES; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 67650410440     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-162123     Document Type: Article

References (51)

1. Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem. 2006;99:690-705. (Pubitemid 44521989)
2. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999; 10:463-471. (Pubitemid 29205482)
3. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382:635-638. (Pubitemid 26268957)
4. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med. 1997; 185:111-120. (Pubitemid 27039446)
5. Semerad CL, Christopher MJ, Liu F, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood. 2005;106:3020-3027. (Pubitemid 41565894)
6. Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med. 1998;4:72-77. (Pubitemid 28133082)
7. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102:2728-2730. (Pubitemid 37248839)
8. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106:1867-1874. (Pubitemid 41208607)
9. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non- Hodgkin's lymphoma. J Clin Oncol. 2004;22: 1095-1102. (Pubitemid 41095043)
10. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14:2519-2526.
11. Konopleva M, Andreeff M. Targeting the leukemia microenvironment. Curr Drug Targets. 2007;8: 685-701.
12. Burger JA, Burkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 2007;137:288-296. (Pubitemid 46650259)
13. Reuss-Borst MA, Klein G, Waller HD, Muller CA. Differential expression of adhesion molecules in acute leukemia. Leukemia. 1995;9:869-874.
14. Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003;9:1158-1165. (Pubitemid 37173700)
15. Tallman MS. New agents for the treatment of acute myeloid leukemia. Best Pract Res Clin Haematol. 2006;19:311-320. (Pubitemid 43315459)
16. de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol. 2007;62:214-226.
17. Del Poeta G, Bruno A, Del Principe MI, et al. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr Cancer Drug Targets. 2008;8:207-222.
18. Jordheim LP, Dumontet C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta. 2007;1776: 138-159. (Pubitemid 350061069)
19. Eisele L, Klein-Hitpass L, Chatzimanolis N, et al. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia. Acta Haematol. 2007; 117:8-15. (Pubitemid 46012418)
20. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15:875-890. (Pubitemid 32529886)
21. Schröder JK, Kirch C, Seeber S, Schutte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol. 1998;103:1096-1103. (Pubitemid 29012650)
22. Westervelt P, Lane AA, Pollock JL, et al. Highpenetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood. 2003;102:1857-1865. (Pubitemid 37022583)
23. Miller CL, Lai B. Human and mouse hematopoietic colony-forming cell assays. Methods Mol Biol. 2005;290:71-89.
24. Rettig MP, Ritchey JK, Meyerrose TE, Haug JS, DiPersio JF. Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graftversus- host disease. Mol Ther. 2003;8:29-41.
25. Gross S, Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell. 2005;7:5-15. (Pubitemid 40126378)
26. Luker GD, Pica CM, Song J, Luker KE, Piwnica- Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat Med. 2003;9:969-973. (Pubitemid 36889943)
27. Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ. A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1999;96:15103-15108.
28. Yuan W, Payton JE, Holt MS, et al. Commonly dysregulated genes in murine APL cells. Blood. 2007;109:961-970. (Pubitemid 46220640)
29. Wojiski S, Lee B, Kindler T, et al. Leukemic promyelocytes possess self-renewal capacity and leukemia stem cell properties in a mouse model of acute promyelocytic leukemia [abstract]. Blood. 2007;110:3373a.
30. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol. 2001;29:448-457.
31. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-1667.
32. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 1998;91:2387-2396. (Pubitemid 28155513)
33. Nilsson SK, Johnston HM, Coverdale JA. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood. 2001;97:2293-2299.
34. Allouche M, Charrad RS, Bettaieb A, Greenland C, Grignon C, Smadja-Joffe F. Ligation of the CD44 adhesion molecule inhibits drug-induced apoptosis in human myeloid leukemia cells. Blood. 2000;96:1187-1190. (Pubitemid 30616894)
35. Fornaro M, Tallini G, Zheng DQ, Flanagan WM, Manzotti M, Languino LR. p27(kip1) acts as a downstream effector of and is coexpressed with the beta1C integrin in prostatic adenocarcinoma. J Clin Invest. 1999;103:321-329.
36. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NFkappa B (RelB/p50) in myeloma cells. Oncogene. 2003;22:2417-2421. (Pubitemid 36560725)
37. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood. 2004;104:550-557.
38. Spoo AC, Lubbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109:786-791. (Pubitemid 46105982)
39. Miyauchi J, Kelleher CA, Wang C, Minkin S, McCulloch EA. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood. 1989;73:1272-1278. (Pubitemid 19107433)
40. te Boekhorst PA, Lowenberg B, Sonneveld P. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia. 1994;8:1480-1486.
41. Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado AM, Jasiok M. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood. 1991;78:2674-2679.
42. Kim HK, De La Luz Sierra M, Williams CK, Gulino AV, Tosato G. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood. 2006;108:812-820. (Pubitemid 44154612)
43. Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349: 743-752. (Pubitemid 37010778)
44. Möller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia. 2003;17:203-210. (Pubitemid 36175907)
45. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83-85. (Pubitemid 18083553)
46. Tassone P, Neri P, Burger R, et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res. 2005; 11:4251-4258. (Pubitemid 40791592)
47. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood. 1996;88:2250-2258.
48. Jundt F, Probsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood. 2004;103:3511-3515. (Pubitemid 38525685)
49. Kimlinger T, Kline M, Kumar S, Lust J, Witzig T, Rajkumar SV. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. Haematologica. 2006;91: 1033-1040. (Pubitemid 44204768)
50. Dierks C, Grbic J, Zirlik K, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med. 2007;13:944-951.
51. Nervi B, Ramirez P, Holt M, et al. CXCR4/SDF-1 is a key regulator for leukemia migration and homing to the BM: Impact of AMD3100 on in vivo response to chemotherapy [abstract]. Blood. 2006;108:171a. Abstract 569.